vs
赫氏（HXL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是赫氏的1.5倍（$772.1M vs $501.5M），Revvity净利率更高（12.7% vs 7.4%，领先5.3%），赫氏同比增速更快（9.9% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 0.1%）
赫氏是总部位于美国康涅狄格州斯坦福德的上市工业材料企业，专注于结构材料的研发与生产，由加州增强塑料公司、汽巴复合材料业务、赫克力士复合材料产品部门合并组建。其产品覆盖商用、军工、休闲等市场，广泛应用于军民飞机、航天运载火箭、卫星、风电叶片、运动器材等领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HXL vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$501.5M
营收增速更快
HXL
高出4.0%
5.9%
净利率更高
RVTY
高出5.3%
7.4%
两年增速更快
RVTY
近两年复合增速
0.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $501.5M | $772.1M |
| 净利润 | $37.2M | $98.4M |
| 毛利率 | 26.9% | — |
| 营业利润率 | 11.5% | 14.5% |
| 净利率 | 7.4% | 12.7% |
| 营收同比 | 9.9% | 5.9% |
| 净利润同比 | 28.7% | 3.9% |
| 每股收益（稀释后） | $0.49 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HXLRVTY
| Q1 26 | $501.5M | — | ||
| Q4 25 | $491.3M | $772.1M | ||
| Q3 25 | $456.2M | $698.9M | ||
| Q2 25 | $489.9M | $720.3M | ||
| Q1 25 | $456.5M | $664.8M | ||
| Q4 24 | $473.8M | $729.4M | ||
| Q3 24 | $456.5M | $684.0M | ||
| Q2 24 | $500.4M | $691.7M |
净利润HXLRVTY
| Q1 26 | $37.2M | — | ||
| Q4 25 | $46.4M | $98.4M | ||
| Q3 25 | $20.6M | $46.7M | ||
| Q2 25 | $13.5M | $53.9M | ||
| Q1 25 | $28.9M | $42.2M | ||
| Q4 24 | $5.8M | $94.6M | ||
| Q3 24 | $39.8M | $94.4M | ||
| Q2 24 | $50.0M | $55.4M |
毛利率HXLRVTY
| Q1 26 | 26.9% | — | ||
| Q4 25 | 24.6% | — | ||
| Q3 25 | 21.9% | 53.6% | ||
| Q2 25 | 22.8% | 54.5% | ||
| Q1 25 | 22.4% | 56.5% | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 23.3% | 56.3% | ||
| Q2 24 | 25.3% | 55.7% |
营业利润率HXLRVTY
| Q1 26 | 11.5% | — | ||
| Q4 25 | 12.5% | 14.5% | ||
| Q3 25 | 7.9% | 11.7% | ||
| Q2 25 | 6.1% | 12.6% | ||
| Q1 25 | 9.7% | 10.9% | ||
| Q4 24 | 1.9% | 16.3% | ||
| Q3 24 | 11.5% | 14.3% | ||
| Q2 24 | 14.3% | 12.4% |
净利率HXLRVTY
| Q1 26 | 7.4% | — | ||
| Q4 25 | 9.4% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 2.8% | 7.5% | ||
| Q1 25 | 6.3% | 6.4% | ||
| Q4 24 | 1.2% | 13.0% | ||
| Q3 24 | 8.7% | 13.8% | ||
| Q2 24 | 10.0% | 8.0% |
每股收益（稀释后）HXLRVTY
| Q1 26 | $0.49 | — | ||
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $54.1M | $919.9M |
| 总债务越低越好 | $998.1M | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $2.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资HXLRVTY
| Q1 26 | $54.1M | — | ||
| Q4 25 | $71.0M | $919.9M | ||
| Q3 25 | $90.5M | $931.4M | ||
| Q2 25 | $77.2M | $991.8M | ||
| Q1 25 | $89.2M | $1.1B | ||
| Q4 24 | $125.4M | $1.2B | ||
| Q3 24 | $98.2M | $1.2B | ||
| Q2 24 | $75.4M | $2.0B |
总债务HXLRVTY
| Q1 26 | $998.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HXLRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B |
总资产HXLRVTY
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $12.2B | ||
| Q3 25 | $2.8B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.8B | $12.4B | ||
| Q4 24 | $2.7B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.8B | $13.4B |
负债/权益比HXLRVTY
| Q1 26 | 0.79× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 3.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流HXLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $125.5M | $182.0M | ||
| Q3 25 | $110.2M | $138.5M | ||
| Q2 25 | $23.3M | $134.3M | ||
| Q1 25 | $-28.5M | $128.2M | ||
| Q4 24 | $162.6M | $174.2M | ||
| Q3 24 | $90.1M | $147.9M | ||
| Q2 24 | $44.2M | $158.6M |
自由现金流HXLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $107.3M | $161.8M | ||
| Q3 25 | $96.5M | $120.0M | ||
| Q2 25 | $8.0M | $115.5M | ||
| Q1 25 | $-54.6M | $112.2M | ||
| Q4 24 | $144.0M | $149.8M | ||
| Q3 24 | $73.3M | $125.6M | ||
| Q2 24 | $21.3M | $136.6M |
自由现金流率HXLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 21.8% | 21.0% | ||
| Q3 25 | 21.2% | 17.2% | ||
| Q2 25 | 1.6% | 16.0% | ||
| Q1 25 | -12.0% | 16.9% | ||
| Q4 24 | 30.4% | 20.5% | ||
| Q3 24 | 16.1% | 18.4% | ||
| Q2 24 | 4.3% | 19.7% |
资本支出强度HXLRVTY
| Q1 26 | 3.2% | — | ||
| Q4 25 | 3.7% | 2.6% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 5.7% | 2.4% | ||
| Q4 24 | 3.9% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 4.6% | 3.2% |
现金转化率HXLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.70× | 1.85× | ||
| Q3 25 | 5.35× | 2.97× | ||
| Q2 25 | 1.73× | 2.49× | ||
| Q1 25 | -0.99× | 3.03× | ||
| Q4 24 | 28.03× | 1.84× | ||
| Q3 24 | 2.26× | 1.57× | ||
| Q2 24 | 0.88× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HXL
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
